EverHint – EMA 10/30 Crossover – Top 15 Buy and Top 5 Sell Signals for Sep 14, 2026
Excerpt: 20 signals (from 54 total). Technology leads (11). price range $6-$290. 3 with insider selling.
What This Signal Is
Detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30), generating both buy and sell signals. Uses two EMAs instead of EMA + SMA, making it more responsive to price changes and better suited for capturing short-to-medium term momentum shifts.
Entry Criteria:
- Buy: EMA10 crosses above EMA30
- Sell: EMA10 crosses below EMA30
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 1-4 weeks | Risk level: Medium
Market Context
Equity markets are experiencing a mild broad-based pullback on September 14, 2026, with the S&P 500, Nasdaq, and Dow Jones all closing in the red. The technology-heavy Nasdaq leads declines at -0.56%, suggesting some softness in growth-oriented names. Despite the negative price action, losses remain modest and do not signal a dramatic shift in trend — more of a consolidation or light profit-taking session than a meaningful reversal.
The more notable development is the VIX, which surged nearly 8% to 17.10. While this level remains within a historically moderate range, the sharp single-day spike indicates that options markets are pricing in greater near-term uncertainty. For EMA-based crossover signals like ema10/ema30, elevated intraday volatility can increase the risk of false breakouts and whipsaw behavior, where price briefly crosses a moving average threshold before reversing. Traders should be mindful of tighter stop-loss discipline and may consider waiting for confirmation before acting on fresh crossover signals.
With Technology leading signal generation at 54 total signals, the sector rotation picture warrants attention. Technology tends to be sensitive to shifts in risk appetite, and the combination of a rising VIX and Nasdaq underperformance suggests some rotation out of high-beta growth exposure. EMA crossover strategies in this environment may perform better in more defensive or momentum-stable sectors, while technology signals carry slightly higher noise risk until volatility stabilizes.
🟢 Buy Signals (15 of 18 total)
Ranked by RSI (lower RSI for buy signals = more oversold)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | AUR | Aurora Innovation, Inc. | Technology | $6.46 | — | $12.7B |
| 2 | AZTA | Azenta, Inc. | Healthcare | $32.04 | — | $1.5B |
| 3 | CI | Cigna Corporation | Healthcare | $290.05 | — | $76.6B |
| 4 | DRI | Darden Restaurants, Inc. | Consumer Cyclical | $218.61 | — | $25.0B |
| 5 | DSGX | The Descartes Systems ... | Technology | $80.02 | — | $6.9B |
| 6 | GPI | Group 1 Automotive, Inc. | Consumer Cyclical | $284.01 | — | $3.4B |
| 7 | KR | The Kroger Co. | Consumer Defensive | $60.91 | — | $37.3B |
| 8 | MDLZ | Mondelez International... | Consumer Defensive | $62.39 | — | $79.6B |
| 9 | MNDY | monday.com Ltd. | Technology | $96.11 | — | $4.1B |
| 10 | MOH | Molina Healthcare, Inc. | Healthcare | $214.07 | — | $11.2B |
| 11 | OLLI | Ollie's Bargain Outlet... | Consumer Defensive | $77.02 | — | $4.7B |
| 12 | PACS | PACS Group, Inc. | Healthcare | $44.55 | — | $7.1B |
| 13 | PM | Philip Morris Internat... | Consumer Defensive | $194.86 | — | $303.7B |
| 14 | S | SentinelOne, Inc. | Technology | $22.61 | Sell -$1,899,353 | $7.6B |
| 15 | TKO | TKO Group Holdings, Inc. | Communication Services | $193.72 | — | $14.5B |
🔴 Sell Signals (5 of 36 total)
Ranked by RSI (higher RSI for sell signals = more overbought)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | APO | Apollo Global Manageme... | Financial Services | $128.31 | — | $73.9B |
| 2 | ARXS | Arxis, Inc. Class A Co... | $49.11 | — | $2.0B | |
| 3 | ASH | Ashland Inc. | Basic Materials | $69.67 | — | $3.2B |
| 4 | BAC | Bank of America Corpor... | Financial Services | $59.47 | — | $422.0B |
| 5 | BEKE | KE Holdings Inc. | Real Estate | $16.70 | — | $18.4B |
Field Notes
Sector concentration: Technology (11), Financial Services (7), Healthcare (6)
Insider selling (7d): S (SentinelOne, Inc., -$1,899,353)
Data coverage: 5.6% insider (7d), 0.0% congressional (30d), 0.0% earnings, 9.3% news (7d)
Peer Analysis
APO (Apollo Global Management, Inc.): Leads 5 peers: CG ($41.82), BX ($128.29), BAM ($46.63), ARES ($131.52), KKR ($102.27)
DSGX (The Descartes Systems Group Inc.): Leads 5 peers: PCTY ($147.97), APPF ($221.87), NICE ($106.69), LYFT ($15.90), SRAD ($13.20)
Recent Headlines
APO (Apollo Global Management, Inc.)
- Apollo Global Management, Inc. (APO) Presents at Barclays 24th Annual Global Financial Services Conference Transcript
BAC (Bank of America Corporation)
- Stock Market Today, Sept. 14: Bank of America Slides on Investment Banking Fee Surprise
- QUICK SPARK: Big Bank Stocks Tumble After Moynihan's Grim Outlook
- Bank of America Stock Slides Monday: What's Driving the Action?
- Bank of America Sees Resilient Consumers, Strong Loan Growth and Rising NII
- Bank of America CEO sees at least 10% drop in Q3 investment banking fees
- Bank of America expects third-quarter investment banking fees to fall more than 10%; shares slide
Vlad's Take
Today's signals: Strong sector concentration in Technology (11 signals) suggests sector-specific rotation. 3 signals showing insider selling warrant caution.
Trading tips for this strategy:
- Entry timing: Enter on pullback after crossover or at crossover close price
- Position sizing: Start with 2-3% of portfolio per signal (swing trade size)
- Stop loss: Below recent swing low for buys, above recent swing high for sells
- Take profit: 5-10% target for swings, or trail stop at EMA10
- Time stop: Exit if crossover reverses within 1-2 weeks (failed signal)
Risk warning: EMA crossovers generate more signals but higher whipsaw risk in ranging markets. Use with trend filter (price vs SMA200)
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If you found this useful, a quick like, share, or subscribe keeps EverHint moving forward.